Fresenius appoints Marc-Alexander Mahl to Management Board
Fresenius appoints Marc-Alexander Mahl to its Management Board from 1 November. He will oversee Kabi; CFO Sara Hennicken stays through 2032.
Fresenius appoints Marc-Alexander Mahl to its Management Board from 1 November. He will oversee Kabi; CFO Sara Hennicken stays through 2032.
Incyte Biosciences Germany has appointed Sabine Hoffmann as Director Government Affairs, creating a new role for policy dialogue.
Serviceplan Boosting Health appoints Christian Necker as Managing Director to advance consulting, growth and AI-supported processes.
Fresenius Medical Care names Shervin J. Korangy CEO and aligns its China strategy with long-term profitable growth and market leadership.
Tobias Boldt will move from Bayer to Schwabe in 2027, taking over as CCO for the OTC and consumer health group.
Beiersdorf names Heike Fischer to lead Pharmacy D/CH, giving her responsibility for the Derma business in Germany and Switzerland.
Dr. Ulrike Banning takes over Medical Knowledge Solutions at Vidal MMI, a business area focused on medical and pharmaceutical information.
Neovii Pharmaceuticals AG names Duncan Ferguson as Chief Commercial Officer to lead global commercial expansion and partnerships.
The GA has named Bionorica CEO Prof. Michael Popp an honorary member, recognizing his work in phytotherapy and natural product research.
Codis has created the Chief Commercial Officer role and appointed Steven Facer to align Sales, Marketing and Business Development globally.
Pharming has announced the immediate departure of CEO Fabrice Chouraqui. Leverne Marsh and Kenneth Lynard will serve as interim co-CEOs.
Ugur Sahin and Özlem Türeci have named their new Mainz-based company Arife. It will focus on next-generation mRNA medicines.
Roche plans to nominate Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to its Board in March 2027. Shareholders will vote at the AGM.
LINDA AG is reshaping its executive board: Dr. Sven Simons becomes CEO, Dr. Christina Froböse joins, and Sebastian Kropp remains.
Anavo Therapeutics appoints Vincent G. Brichard as Chairman as the company advances phosphatase programs in three disease areas.
Travere Therapeutics plans a CEO transition, with Bradley L. Campbell set to succeed Eric Dube on December 1, 2026.
Bavarian Nordic appoints Tarja Stenvall as CEO. The pharma executive will take over from Paul Chaplin on October 15, 2026.
Takeda says R&D chief Andy Plump will retire in June 2027, with a successor process and transition planned as the late-stage pipeline advances.
Hovione appoints Stefan Doboczky as CEO. The board chair will take operational charge of the pharma technology group in April 2027.
Jenny Blum has joined BVMed as sustainability officer. The former DIN team coordinator will cover ESG topics and standardisation processes.
Looking for a new partner in pharma and healthcare marketing?
Visit our agency finder